ArticleOncoTargets and therapy2019

Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy.

Guan-Zhang Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.